FDA Clearance Tracker · P240011-S011
Altaviva
Last checked: Nov 20, 2026Latest source record: Mar 26, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 26, 2026
Approved
Time to decision
30 days
Received Feb 24, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240011-S011
- Device name
- Altaviva
- Applicant
- Medtronic Neuromodulation
- Applicant location
- Minneapolis, MN
- Received
- Feb 24, 2026
- Decided
- Mar 26, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240011
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
approval for several administrative changes to the protocol and for Medtronic Neuromodulation to provide the commercial Altaviva system at no cost to study sites
Source documents
Other decisions for Medtronic Neuromodulation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240011 · Decided Sep 18, 2025 · 532 days after receipt
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.